Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring

Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring

Abstract Background Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive treatment which allows delivery of an ablative radiation dose with high accuracy and precision. SABR is an established treatment for both primary and secondary liver malignancies, and technological advances have imp...

Full description

Bibliographic Details
Main Authors: Yoo Young Dominique Lee, Doan Trang Nguyen, Trevor Moodie, Ricky O’Brien, Anne McMaster, Andrew Hickey, Nicole Pritchard, Per Poulsen, Elizaveta Mitkina Tabaksblat, Britta Weber, Esben Worm, David Pryor, Julie Chu, Nicholas Hardcastle, Jeremy Booth, Val Gebski, Tim Wang, Paul Keall
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Stereotactic radiotherapy
Liver Cancer
Hepatocellular carcinoma
Oligometastases
Kilovoltage intrafraction monitoring
LARK trial
Online Access:https://doi.org/10.1186/s12885-021-08184-x

Internet

https://doi.org/10.1186/s12885-021-08184-x

Similar Items